In 2014, Spain’s internal expenditure on biotechnology R&D increased 1.5% to €1,450 million ($1.6 billion), or 11% of Spain’s annual R&D expenditures. The public administration sector accounted for 38% of biotech R&D internal expenditures, a 0.7% decrease. The business sector represented 37%, a 3.8% increase. The number of firms conducting R&D in the biotech industry rose 9.8%. Within the business sector, services accounted for 67% of internal R&D expenditures, industry represented 28% and agriculture made up 5%. Activity wise, R&D services and pharmacy accounted for 51% and 19% of R&D expenditures, respectively. The higher education sector accounted for 25%, a 1.2% increase. Fifty-one percent of internal biotech–related R&D was financed by the public administration sector. The business sector, foreign sources, higher education and private nonprofits financed 30%, 12%, 5% and 2%, respectively. Regarding external expenditures, purchases of biotech R&D equaled €163 million, with 24% of expenditures made outside of Spain. Business, human health and food accounted for 85%, 53% and 34% of external expenditures, respectively.

Source: Instituto Nacional de Estadística